| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ERC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于ERC2抗体的参考文献示例(注：内容为模拟生成，实际文献需根据具体数据库查询)：
1. **文献名称**：*ERC2/EWS fusion gene detection by immunohistochemistry in Ewing sarcoma*
**作者**：Sore et al.
**摘要**：本研究开发了一种针对ERC2-EWS融合蛋白的特异性抗体，用于尤文肉瘤的病理诊断。通过免疫组化验证，证实其在区分ERC2相关肿瘤中的高敏感性和特异性。
2. **文献名称**：*ERC2 regulates synaptic vesicle release and neuronal plasticity*
**作者**：Kaeser et al.
**摘要**：探讨ERC2蛋白在神经突触囊泡释放中的功能，利用基因敲除小鼠模型及ERC2抗体进行定位分析，发现ERC2通过与RIM蛋白相互作用调控神经递质释放。
3. **文献名称**：*ERC2 as a diagnostic marker in neuroendocrine tumors*
**作者**：Schaefer & Nakagawa
**摘要**：通过免疫印迹和免疫荧光技术，验证ERC2抗体在神经内分泌肿瘤组织中的高表达，提示其作为潜在诊断标志物的价值。
4. **文献名称**：*Structural analysis of the ERC2 protein complex in cancer cells*
**作者**：Takagi et al.
**摘要**：利用共聚焦显微镜和ERC2特异性抗体解析ERC2与ELKS家族蛋白的相互作用，揭示其在维持细胞骨架和肿瘤转移中的分子机制。
建议通过PubMed或Google Scholar以“ERC2 antibody”或“ERC2/CAST2”为关键词检索最新文献。
ERC2 (ETV1-related carcinoma antigen 2) antibodies are primarily associated with research in urological cancers, particularly prostate cancer. ERC2. also known as ERG (ETS-related gene), encodes a transcription factor belonging to the ETS family, which regulates genes involved in cell proliferation, differentiation, and apoptosis. The ERG gene frequently undergoes chromosomal rearrangements, most commonly fusing with the TMPRSS2 promoter in prostate cancer, resulting in androgen receptor-driven overexpression of ERG. This fusion event occurs in approximately 50% of prostate cancers, making ERG a key diagnostic and prognostic biomarker.
ERC2 antibodies specifically target the ERG protein product, enabling detection of its overexpression in tumor tissues through immunohistochemistry (IHC). These antibodies have become valuable tools in pathology for identifying TMPRSS2-ERG gene fusion-positive prostate cancers, aiding in differential diagnosis and risk stratification. Beyond prostate cancer, ERG expression has been observed in other malignancies, including Ewing's sarcoma and acute myeloid leukemia, though with lower prevalence.
Recent studies explore ERC2 antibodies' potential in targeted therapies and as predictors of treatment response. However, challenges remain in standardizing detection methods and understanding ERG's precise oncogenic mechanisms. Their clinical utility continues to evolve alongside molecular pathology advancements in precision oncology.
×
